# DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

> **NCT04447404** · PHASE2 · TERMINATED · sponsor: **Durect** · enrollment: 2 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **DRUG:** DUR-928
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04447404
- **Lead sponsor:** Durect
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-21
- **Primary completion:** 2021-03-04
- **Final completion:** 2021-03-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** low enrollment
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447404, "DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04447404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*